Atuka is science-driven CRO, with world-leading expertise, particularly in the Parkinson’s disease (PD) field. We work with our clients in a collaborative way and position ourselves as an extension of our client’s scientific team. Atuka provides bespoke contract research services in PD and related neurological conditions. We provide cutting-edge, rodent, and non-human primate models of PD to evaluate potential symptomatic (motor and non-motor symptoms such as cognition) and disease-modifying treatments. Atuka also offers non-GLP toxicity, biodistribution (e.g. for gene therapies), medicinal chemistry, DMPK and in-vivo imaging services to aid development of novel therapeutics.
Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Quantitative Systems Pharmacology (QSP) addresses the most complex challenges in drug development by combining computational modeling and experimental data to examine the relationships between a drug, biological system, and disease process. Certara’s QSP simulator and services can predict dose-response relationship between administered viral load and target protein expression. For Gene Therapy and Neurological Diseases, these tools increase confidence around dosing, immunogenicity, and special populations.
bit.bio combines the concepts of coding and biology to provide human cells for research, drug discovery and cell therapy, enabling a new generation of medicines for every patient, everywhere.
This is possible with our proprietary cell coding technology opti-oxTM - a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through direct reprogramming of stem cells.
Genomenon is a genomic health IT company that keeps pace with the constant advancements made in genomics and connects that research to patient DNA to help diagnose and treat patients with rare genetic diseases and cancer. Mastermind Genomic Landscapes inform pharmaceutical companies on precision medicine development, deliver genomic biomarkers for clinical trial target selection, and support CDx regulatory submissions with empirical evidence. Genomenon was named Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan
GemPharmatech is a leading provider of genetically engineered mouse models (GEMMs) and services to global preclinical R&D communities. We specialize in developing animal models using cutting-edge gene-editing technologies with a large collection of cKO/KO (conditional knockout/knockout) mice, humanized mice, immunodeficient mice, and germ-free mice.
Ananda Devices (AD) specializes in high throughput nervous system on-a-chip technology development. Their NeuroHTS(TM) enables analysis of 7 key factors of neuronal phenotypes for 3000 neurons on each plate with batch to batch reproducibility of 88%, thereby generating big data to provide robust and predictive insights. AD has developed several human physiologically relevant disease models such as Parkinsons, Alzheimers and ALS that are adopted by top pharma companies for preclinical and translational research.
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
We envision a world where a quantitative insight into how proteins interact transforms our understanding of how the biological world operates, and helps all of us make better decisions about how we diagnose diseases, develop treatments and maintain our well-being.
By delivering the world’s best tools, software, analytics and services for analyzing protein interactions and making them universally available in the lab, clinic or home, we are making this vision a reality.
SiteRx is a physician-driven platform leveraging the patient-provider relationship to introduce research at the point of care. SiteRx has a growing network of 1,200+ neurologists and PCPs across 28 US states. SiteRx integrates with providers’ EHRs and uses AI to review structured/unstructured data to assist the HCP in identifying trial matches. SiteRx provides support to ensure pre-qualified and motivated patients are connected to trial sites at speed and with full health records.
Aptah Bio is a biotech startup focused in digital molecular design used for RNA therapy. Aptah aims to revolutionize the way diseases are treated through its patented technology platform called ASMO – Aptah Spliceosome Modulation Oligonucleotide. Aptah focuses on harnessing and utilizing the spliceosome machinery for modulating and correcting ribonucleic acid (RNA) transcript splicing and other post-transcriptional processes. Its platform technology provides a unique and powerful therapeutic approach to treating various diseases associated with gene dysregulation, which may include more than 15% of all genetic disorders.
Renishaw Neuro Solutions enables direct-to-target delivery for oncology applications. Using the neuroinfuse™ drug delivery system, predictable and translatable preclinical and clinical trials can become a reality. Our Lab2Clinic™ service supports our partners through the preclinical journey, translation into clinical trials and scaled-up commercialisation. We have a wide geographical reach, and we focus on promoting long-term partnerships. All this is underpinned by our FDA-cleared, CE-marked stereotactic products borne out of a +45-year precision engineering heritage.
Axol is a leading provider of product and service solutions in the iPSC-based neuroscience, immune cell, and cardiac modeling for drug discovery and screening markets. Our custom research capabilities in gene editing, electrophysiology, reprogramming and differentiation means we can offer customers validated ready-to-use cell lines and a suite of services bolstered by deep scientific expertise and robust functional data - all with shorter lead times.
Lipotype is the leading lipidomics service provider for every researcher. Our mass spectrometry-based technology identifies more than 4200 individual lipids in minutes and routinely covers a rich variety of sample types while requiring only minimal sample amounts. Lipotype Lipidomics empowers scientists from biotech, pharma, food industry, cosmetics, and academia to reach their research goals through comparable, quantitative lipidomics data. Contact our research project support, order your lipidomics services, send in your samples, and study your reports in as little as two weeks.